Articles

Find an Article

Filter articles

Applied Filters

Showing 81 to 90 of 256 results

IP and investment: put your money where your mouth is

EU24-11-2016Dimitar Georgiev

Intellectual property in the life sciences arena can be an attractive investment target, but a long process of evaluation must take place first, cautions Dimitar Georgiev, founder and CEO of Paralax Life Sciences.

Arrow declarations: striking at the heart of commercial uncertainty

EU, UK08-11-2016Richard Roberts

To overcome a crowded patent market, a potential solution is to seek a declaration of obviousness, which has a basis in UK law stemming from Arrow Generics v Merck. Richard Roberts of Potter Clarkson reports.

IP Life Sciences Exchange: a preview

Germany07-11-2016

The IP Life Sciences Exchange, an event for senior IP decision-makers from the life sciences sector, will take place on November 15 and 16 in Munich, Germany. LSIPR previews some of the most interesting sessions.

Brexit: a fresh start for SPCs?

EU, UK20-10-2016Paul England and Matthew Royle

The UK’s vote to leave the EU may allow Britain to replace the SPC regulation—an often-criticised piece of law—and take a fresh approach to the system governing these rights, say Paul England and Matthew Royle of Taylor Wessing.

IP service providers: a more cost-effective solution post M&A?

International18-10-2016Melissa Pillote

With specialist IP providers offering post-M&A services at lower cost than traditional law firms, have clients been overspending in the past? Melissa Pillote on behalf of Dennemeyer reports.

Russian patent law: Natural selection

Russia17-10-2016Valery Djermakian

There is some debate among Russian legal professionals about whether “selection inventions” are considered patentable, but the answer seems clear, says Valery Djermakian of Gorodissky & Partners.

Technology transfer: A smart way of working

International14-10-2016Montserrat González-Álvarez

‘Technological intelligence’ is very important for extracting maximum value from technology transfer deals, and life sciences companies should use it to their advantage, says Montserrat González-Álvarez of Leyva, Montenegro, Trigueros Abogados.

Pay-for-delay: Play by the rules

EU14-10-2016Bernd Allekotte and Franz Zimmer

The EU General Court’s decision in September to fine Lundbeck nearly €150 million over several pay-for-delay deals will encourage the European Commission to take further action against similar agreements, say Bernd Allekotte and Franz Zimmer of Grünecker.

The post-Brexit picture for orphan drugs

EU, UK13-10-2016Kei Enomoto

The UK government must ensure that the vital market for orphan drugs will continue to prosper following Brexit, says Kei Enomoto of Maucher Jenkins.

Working together wisely

International12-10-2016Oliver Laing and Tony Proctor

In a world where research projects are increasingly carried out by several parties in different countries, companies should consider a number of IP-related issues before embarking on multiterritorial collaborations, say Oliver Laing and Tony Proctor of Potter Clarkson.

Showing 81 to 90 of 256 results

LSIPR